{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T22:44:17Z","timestamp":1744497857188},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11136-024-03622-2","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T20:26:12Z","timestamp":1712348772000},"page":"1527-1540","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV)"],"prefix":"10.1007","volume":"33","author":[{"given":"Mourad","family":"Abbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrieri","family":"Patrizia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcellin","family":"Fabienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bourliere","family":"Marc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parlati","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrat","family":"Fabrice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duracinsky","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Protopopescu","family":"Camelia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"issue":"3","key":"3622_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/17474124.2017.1285227","volume":"11","author":"F Marcellin","year":"2017","unstructured":"Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: Current knowledge and outstanding issues. Expert Review of Gastroenterology & Hepatology, 11(3), 259\u2013268. https:\/\/doi.org\/10.1080\/17474124.2017.1285227","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"2","key":"3622_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2014.04.003","volume":"61","author":"ZM Younossi","year":"2014","unstructured":"Younossi, Z. M., et al. (2014). Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. Journal of Hepatology, 61(2), 228\u2013234. https:\/\/doi.org\/10.1016\/j.jhep.2014.04.003","journal-title":"Journal of Hepatology"},{"issue":"1","key":"3622_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139\u2013144. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"3622_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407\u2013415. https:\/\/doi.org\/10.1016\/0197-2456(89)90005-6","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"3622_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erp.11.9","volume":"11","author":"MT King","year":"2011","unstructured":"King, M. T. (2011). A point of minimal important difference (MID): A critique of terminology and methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 171\u2013184. https:\/\/doi.org\/10.1586\/erp.11.9","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"5","key":"3622_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s0895-4356(03)00044-1","volume":"56","author":"RD Crosby","year":"2003","unstructured":"Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395\u2013407. https:\/\/doi.org\/10.1016\/s0895-4356(03)00044-1","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"3622_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00435226","volume":"2","author":"E Lydick","year":"1993","unstructured":"Lydick, E., & Epstein, R. S. (1993). Interpretation of quality of life changes. Quality of Life Research, 2(3), 221\u2013226. https:\/\/doi.org\/10.1007\/BF00435226","journal-title":"Quality of Life Research"},{"issue":"11","key":"3622_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/s0895-4356(96)00206-5","volume":"49","author":"DA Redelmeier","year":"1996","unstructured":"Redelmeier, D. A., Guyatt, G. H., & Goldstein, R. S. (1996). Assessing the minimal important difference in symptoms: A comparison of two techniques. Journal of Clinical Epidemiology, 49(11), 1215\u20131219. https:\/\/doi.org\/10.1016\/s0895-4356(96)00206-5","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7","key":"3622_CR9","doi-asserted-by":"publisher","first-page":"A591","DOI":"10.1016\/j.jval.2015.09.1523","volume":"18","author":"AAM Duracinsky","year":"2015","unstructured":"Duracinsky, A. A. M., Herrmann, S., Lalanne, C., Galano, E., Da Silva, M. H., Carrieri, P. M., & Chassany, O. (2015). \"PIN90 -psychometric validation of the new international questionnaire to assess health-related quality of Life (Hrql) specific to viral hepatitis C: Proqol-Hcv. Value in Health, 18(7), A591\u2013A592. https:\/\/doi.org\/10.1016\/j.jval.2015.09.1523","journal-title":"Value in Health"},{"issue":"5","key":"3622_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582\u2013592. https:\/\/doi.org\/10.1097\/01.MLR.0000062554.74615.4C","journal-title":"Medical Care"},{"issue":"1","key":"3622_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2009.01.024","volume":"63","author":"D Turner","year":"2010","unstructured":"Turner, D., et al. (2010). The minimal detectable change cannot reliably replace the minimal important difference. Journal of Clinical Epidemiology, 63(1), 28\u201336. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.01.024","journal-title":"Journal of Clinical Epidemiology"},{"key":"3622_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens, D. (2013). Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front Psychol, 4, 863. https:\/\/doi.org\/10.3389\/fpsyg.2013.00863","journal-title":"Front Psychol"},{"key":"3622_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4088\/JCP.20f13681","volume":"81","author":"C Andrade","year":"2020","unstructured":"Andrade, C. (2020). Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry, 81, 5. https:\/\/doi.org\/10.4088\/JCP.20f13681","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"3622_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/s0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (1999). Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology, 52(9), 861\u2013873. https:\/\/doi.org\/10.1016\/s0895-4356(99)00071-2","journal-title":"Journal of Clinical Epidemiology"},{"key":"3622_CR15","unstructured":"M. B. Barlow and G. S. Sennett, \"Ketalar (ketamine hydrochloride),\" S Afr Med J, vol. 45, no. 37, p. 1042, Sep 25 1971. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5129883."},{"issue":"6","key":"3622_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555\u2013567. https:\/\/doi.org\/10.1007\/BF00439229","journal-title":"Quality of Life Research"},{"issue":"9","key":"3622_CR17","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","volume":"22","author":"J Maringwa","year":"2011","unstructured":"Maringwa, J., et al. (2011). Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology, 22(9), 2107\u20132112. https:\/\/doi.org\/10.1093\/annonc\/mdq726","journal-title":"Annals of Oncology"},{"issue":"4","key":"3622_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","volume":"38","author":"LF Andrade","year":"2020","unstructured":"Andrade, L. F., Ludwig, K., Goni, J. M. R., Oppe, M., & de Pouvourville, G. (2020). A french value set for the EQ-5D-5L. PharmacoEconomics, 38(4), 413\u2013425. https:\/\/doi.org\/10.1007\/s40273-019-00876-4","journal-title":"PharmacoEconomics"},{"issue":"2","key":"3622_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"Journal of Clinical Epidemiology"},{"key":"3622_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2016.11.016","volume":"82","author":"F Angst","year":"2017","unstructured":"Angst, F., Aeschlimann, A., & Angst, J. (2017). The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies. Journal of Clinical Epidemiology, 82, 128\u2013136. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.11.016","journal-title":"Journal of Clinical Epidemiology"},{"key":"3622_CR21","unstructured":"D. W. Hosmer and S. Lemeshow, Applied logistic regression (Wiley series in probability and mathematical statistics). New York, NY; Chichester: Wiley, 1989."},{"issue":"12","key":"3622_CR22","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jclinepi.2015.03.015","volume":"68","author":"B Terluin","year":"2015","unstructured":"Terluin, B., Eekhout, I., Terwee, C. B., & de Vet, H. C. (2015). Minimal important change (MIC) based on a predictive modeling approach was more precise than MIC based on ROC analysis. Journal of Clinical Epidemiology, 68(12), 1388\u20131396. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.03.015","journal-title":"Journal of Clinical Epidemiology"},{"key":"3622_CR23","unstructured":"M. B. Patrizia Carrieri, Vincent Di Beo, Clovis Lusivika-Nzinga, Cl\u00e9mence Ramier, Saskia Antwerpes, Camelia Protopopescu, 2023 Jean-Marc Lacombe, Stanislas Pol, H\u00e9l\u00e8ne Fontaine, Abbas Mourad, Fabrice Carrat, Martin Duracinsky, Fabienne Marcellin. , \"Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort),\" Quality of Life Research (sous presse)."},{"issue":"5","key":"3622_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","volume":"7","author":"AG Copay","year":"2007","unstructured":"Copay, A. G., Subach, B. R., Glassman, S. D., Polly, D. W., Jr., & Schuler, T. C. (2007). Understanding the minimum clinically important difference: a review of concepts and methods. Spine J, 7(5), 541\u20136. https:\/\/doi.org\/10.1016\/j.spinee.2007.01.008","journal-title":"Spine J"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03622-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:01:10Z","timestamp":1716472870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03622-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3622"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03622-2","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"26 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patrizia Carrieri received research grants from MSD and Intercept unrelated to this work. Marc Bourli\u00e8re reports grants and personal fees from AbbVie, grants and personal fees from Gilead, personal fees from MSD, personal fees from Janssen, personal fees from Boehringher Ingelheim, personal fees from Intercept, and personal fees from BMS, all unrelated to this work. Fabrice Carrat reports grants from INSERM-ANRS during the implementation of this study and personal fees from Imaxio, unrelated to this work. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}